Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) is 6.93% higher on its value in year-to-date trading and has touched a low of $2.66 and a high of $18.07 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ZNTL stock was last observed hovering at around $3.00 in the last trading session, with the day’s gains setting it 0.24%.
Currently trading at $3.24, the stock is 1.29% and -2.44% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.59 million and changing 8.00% at the moment leaves the stock -48.24% off its SMA200. ZNTL registered -79.23% loss for a year compared to 6-month loss of -10.50%. The firm has a 50-day simple moving average (SMA 50) of $3.3211 and a 200-day simple moving average (SMA200) of $6.25915.
The stock witnessed a -3.57% gain in the last 1 month and extending the period to 3 months gives it a 1.25%, and is 1.57% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.78% over the week and 8.21% over the month.
Zentalis Pharmaceuticals Inc (ZNTL) has around 168 employees, a market worth around $249.37M and $40.56M in sales. Profit margin for the company is -442.02%. Distance from 52-week low is 21.80% and -82.07% from its 52-week high. The company has generated returns on investments over the last 12 months (-45.41%).
The EPS is expected to grow by 45.10% this year.
Zentalis Pharmaceuticals Inc (ZNTL) Top Institutional Holders
191.0 institutions hold shares in Zentalis Pharmaceuticals Inc (ZNTL), with institutional investors hold 108.15% of the company’s shares. The shares outstanding are 71.15M, and float is at 57.60M with Short Float at 9.55%. Institutions hold 98.01% of the Float.
The top institutional shareholder in the company is MATRIX CAPITAL MANAGEMENT COMPANY, LP with over 13.96 million shares valued at $57.1 million. The investor’s holdings represent 19.6902% of the ZNTL Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 8.68 million shares valued at $35.49 million to account for 12.2383 of the shares outstanding. The other top investors are EVENTIDE ASSET MANAGEMENT, LLC which holds 8.55 million shares representing 12.0566% and valued at over $34.96 million, while VANGUARD GROUP INC holds 7.9759 of the shares totaling 5.65 million with a market value of $23.13 million.
Zentalis Pharmaceuticals Inc (ZNTL) Insider Activity
The most recent transaction is an insider sale by Lackner Mark, the company’s Chief Scientific Officer. SEC filings show that Lackner Mark sold 4,411 shares of the company’s common stock on Jan 02 ’25 at a price of $3.12 per share for a total of $13762.0. Following the sale, the insider now owns 0.19 million shares.
Still, SEC filings show that on Oct 04 ’24, Vultaggio Vincent (Principal Accounting Officer) disposed off 1,603 shares at an average price of $3.18 for $5098.0. The insider now directly holds 33,855 shares of Zentalis Pharmaceuticals Inc (ZNTL).
